December 10, 2025 04:00 ET | Source: Igyxos TOURS, France, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Igyxos Biotherapeutics, a biotechnology…
INNSBRUCK, Austria, Dec. 9, 2025 /PRNewswire/ -- As cyberattacks continue to challenge even the most resilient organisations, the need for…
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from…
DALLAS, Dec. 2, 2025 /PRNewswire/ -- On December 1, Cango Inc. (NYSE: CANG) ("Cango" or the "Company") announced its unaudited…
November 2025 global sales of 262,065 units, down 0.8% Y/yIn Korea, Kia sold 47,256 units, down 1.6% Y/yOutside of Korea,…
CALGARY, Alberta, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE) announces financial and operating…
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- HP (NYSE: HPQ) Fiscal 2025 GAAP diluted net earnings per share…